News
Mission drives innovation, and innovation improves quality of life
News
Shenzhen International Biotech Conference 2019 – Seeking Cure: The Next-Gen Targeted Therapy
2020-03-21 Views:
On September 11, the Shenzhen International Biotech Conference 2019 (hereinafter referred to as Biotech 2019), with the theme of focusing on new opportunities of science and technology, setting sail for health in Greater Bay Area, was successfully held at the Shenzhen Convention and Exhibition Center.
△ Dr. Yihan Wang, Founder and Chairman of TargetRx, was invited to attend and received an award (fifth from right)
During the conference, KPMG China and the Shenzhen State High-Tech Industrial Innovation Center jointly released the Top 20 Leading Biotechnology Companies in Shenzhen 2019 - Leading Company List and Pioneer Company List after quantitatively assessing related companies in multiple dimensions including team, technology, product, market, and financing. Shenzhen TargetRx Inc. (hereinafter referred to as TargetRx) were among the nine biopharmaceutical companies awarded the title of Pioneer Company.
Professional Forum I
Seeking Cure: The Next-Gen Targeted Therapy
As one of the co-organizers of the conference for the second time, TargetRx, with the support and trust of the Shenzhen Municipal People's Government and the Development and Reform Commission of Shenzhen Municipality, successfully planned and hosted a professional forum: Seeking Cure: The Next-Gen Targeted Therapy, and many well-known biomedical industry experts and investors attended this forum.
Yihan Wang, Founder, Chairman and CEO of Shenzhen TargetRx Inc.
Profile of TargetRx and Key Project Release
Clinical project launch and ribbon cutting ceremony
Forum guests including Academician Yongkui Sun, Professor Ruibao Ren, and Dr. Shuangqing Peng, Dr. Donghui Qin, and special guests including Dr. Zongliang Zou from Liu, Shen & Associates, Mr. Shisheng Wang, General Manager of Futian District Government Guiding Fund, Mr. Xianjia He, Associate Investigator of Shenzhen Nanshan District Science and Technology Innovation Bureau, Mr. Yi Wang, a partner of Shenzhen Suncrest Investment Co., Ltd., and Dr. Yihan Wang, Chairman of TargetRx, participated in the ribbon-cutting ceremony.
Yongkui Sun, Chairman of Shenzhen Ionova Life Science Co., Ltd., and a member of the National Academy of Engineering
Academician Sun explained the meaning of innovative drugs and their significance to the development of new drugs
Ruibao Ren, Director of Shanghai Institute of Hematology
Professor Ren explained the precise diagnosis and treatment of leukemia
Shuangqing Peng, Vice President of Pre-clinical Research Department, Shanghai Medicilon Inc.
Professor Peng described the clinical evaluation of tumor immunotherapy drugs and the strategy of IND application in both China and US
“Innovative and Enterpreneurial Investment on Precision Medicine” Roundtable Seminar
Guests from left to right:
Yihan Wang, Chairman and CEO of TargetRx;
Donghui Qin, Chairman and CEO of Phaeno Therapeutics;
Bo Ying, Founder and CEO of Suzhou Abogen Biosciences;
Yujie Guo, Vice President of Sequoia Capital China
Tel: +86-0755-86934300
3rd Floor, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China
E-mail: 